Christopher A. Newton

OverviewAI-generated summary

Christopher A. Newton's research focuses on the inpatient management of diabetes mellitus, particularly type 2 diabetes, and related metabolic disorders. His work has investigated various insulin regimens, including basal-bolus and basal-plus correction strategies, and compared different insulin types like detemir/aspart versus NPH/regular insulin for hospitalized patients. He has also examined the efficacy of specific medications, such as sitagliptin, for inpatient use and explored discharge algorithms based on HbA1c levels to guide post-hospitalization management.

Beyond medication and regimen studies, Newton's research has addressed critical outcomes related to glycemic control. This includes the GLUCO-CABG trial, which assessed intensive versus conservative glucose control in patients undergoing coronary artery bypass graft surgery. His publications also touch upon severe diabetic complications like ketoacidosis and the confirmation of hypoglycemia in sudden death syndromes using continuous glucose monitoring.

Newton has received federal funding for two NIH grants totaling over $600,000. These grants support research into gene therapy, specifically exploring the genomic and cellular determinants of gene therapy durability and investigating non-viral delivery methods for CRISPR/Cas9 for targeted gene replacement. His scholarship metrics include an h-index of 25 and over 2,400 citations across 43 publications, designating him as a highly cited researcher. He collaborates with other faculty members at the University of Arkansas at Fayetteville.

Metrics

• h-index: 25
• Publications: 43
• Citations: 2,482